Abiopharma

News list

Zura Bio Ltd (ZURA)

SEC News
Jan. 12, 2026, 11:45 UTC

(10% Negative) Zura Bio Ltd (ZURA) Announces Delay in identified Development Timeline Due to Geopolitical Situation, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text

News bot Jan. 29, 2026, 8:57 p.m.

📋 Zura Bio Ltd (ZURA) - Clinical Trial Update

Filing Date: 2026-01-12

Accepted: 2026-01-12 06:45:55

Event Type: Clinical Trial Update

Event Details:

Zura Bio Ltd (ZURA) Announces Clinical Trial Update Zura Bio Ltd (ZURA) provided an update on its clinical development programs. Clinical Development Highlights:

Drug Program: identified
Clinical Stage: clinical trial
Update Type: Trial Timeline Adjustment
Primary Factors: Geopolitical Situation, Patient Enrollment, Regulatory Process
Collaboration: Zura Bio’s
- Targeting immune drivers of autoimmunity, inflammation, and fibrosis Disease Severe, progressive, multisystem autoimmune disease Core features: inflammation, vasculopathy, and fibrosis No therapies are approved that comprehensively address the multisystem pathology of SSc* Program Tibulizumab (BAFF + IL-17A bispecific antibody) Phase 2 TibuSURE clinical study; topline data expected 1H 2027
- Targeting High-Unmet-Need, Multi-Pathway Autoimmune Diseases Nasdaq: ZURA A Phase 2 trial in adults with HS Anticipated Readout: Q4 2026
- anticipated in Q4 2026

🔬 Clinical Development Pipeline (Zura Bio Ltd):

Product	Type	Development Stage	Therapeutic Area	Source
Avastin	DRUG	Phase PHASE1	Macular Degeneration	ClinicalTrials.gov
ORA102 and Avastin	DRUG	Phase PHASE1	Macular Degeneration	ClinicalTrials.gov

💼 Business Developments:

Partnership: Not available
Acquisition: Not available
Licensing: Not available
Regulatory Approval
Executive Changes: Not available

Structured Data:

Company Name: Zura Bio Ltd
Ticker Symbol: ZURA